BRCA-话题@MedSci - williamhill asia

#BRCA#

135篇内容 | 2441人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594080, encodeId=82831594080a3, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, objectType=article, longId=211199, objectId=ffa121119985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa121119985, replyNumber=0, likeNumber=64, createdTime=2021-05-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa121119985, moduleTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ffa121119985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594079, encodeId=7ed015940e9d2, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！, objectType=article, longId=210532, objectId=94d6210532be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d6210532be, replyNumber=0, likeNumber=67, createdTime=2021-04-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d6210532be, moduleTitle=J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=94d6210532be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594078, encodeId=e42a15940e854, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , objectType=article, longId=209040, objectId=19e420904055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e420904055, replyNumber=0, likeNumber=72, createdTime=2021-03-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e420904055, moduleTitle=Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=19e420904055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594077, encodeId=a55915940e7e8, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur J Cancer：激素替代治疗使45岁以上BRCA突变携带者乳腺癌风险增加3倍！, objectType=article, longId=208915, objectId=36f02089159b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36f02089159b, replyNumber=0, likeNumber=76, createdTime=2021-03-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36f02089159b, moduleTitle=Eur J Cancer：激素替代治疗使45岁以上BRCA突变携带者乳腺癌风险增加3倍！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=36f02089159b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594076, encodeId=9b9615940e681, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制 , objectType=article, longId=207722, objectId=7efa20e722e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7efa20e722e0, replyNumber=0, likeNumber=59, createdTime=2021-03-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7efa20e722e0, moduleTitle=Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7efa20e722e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594075, encodeId=f75415940e589, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究, objectType=article, longId=207488, objectId=3be820e4881c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be820e4881c, replyNumber=0, likeNumber=66, createdTime=2021-02-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be820e4881c, moduleTitle=Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3be820e4881c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594074, encodeId=a0ef15940e44c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Br J Cancer：携带BRCA2突变的乳腺癌患者的生存率分析, objectType=article, longId=207348, objectId=628320e3487c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=628320e3487c, replyNumber=0, likeNumber=89, createdTime=2021-02-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=628320e3487c, moduleTitle=Br J Cancer：携带BRCA2突变的乳腺癌患者的生存率分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=628320e3487c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594073, encodeId=ef9615940e38f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, objectType=article, longId=206058, objectId=87ad20605893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87ad20605893, replyNumber=0, likeNumber=61, createdTime=2021-01-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87ad20605893, moduleTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=87ad20605893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594072, encodeId=819c15940e2e2, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM双重磅：不仅是BRCA，乳腺癌风险与这些基因也密切相关！, objectType=article, longId=206030, objectId=3f2e2060300f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f2e2060300f, replyNumber=0, likeNumber=83, createdTime=2021-01-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f2e2060300f, moduleTitle=NEJM双重磅：不仅是BRCA，乳腺癌风险与这些基因也密切相关！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3f2e2060300f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594071, encodeId=bd5115940e1b7, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, objectType=article, longId=205690, objectId=826020569015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=826020569015, replyNumber=0, likeNumber=72, createdTime=2021-01-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=826020569015, moduleTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=826020569015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594070, encodeId=c2a215940e04c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, objectType=article, longId=205519, objectId=bf4a2055190b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf4a2055190b, replyNumber=0, likeNumber=54, createdTime=2021-01-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf4a2055190b, moduleTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf4a2055190b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594069, encodeId=86a91594069b0, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！, objectType=article, longId=204483, objectId=c6282044830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6282044830a, replyNumber=0, likeNumber=68, createdTime=2020-12-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6282044830a, moduleTitle=妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c6282044830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594068, encodeId=9f51159406814, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征, objectType=article, longId=201647, objectId=842c20164e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=842c20164e18, replyNumber=0, likeNumber=59, createdTime=2020-10-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=842c20164e18, moduleTitle=Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=842c20164e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594067, encodeId=8cde159406ee3, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Br J Cancer：ER表达状态对BRCA2突变型乳腺癌预后的影响, objectType=article, longId=201035, objectId=75fa201035f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75fa201035f9, replyNumber=0, likeNumber=55, createdTime=2020-09-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75fa201035f9, moduleTitle=Br J Cancer：ER表达状态对BRCA2突变型乳腺癌预后的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=75fa201035f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594066, encodeId=3c7d159406676, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, objectType=article, longId=200007, objectId=6f2b20000e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2b20000e60, replyNumber=0, likeNumber=80, createdTime=2020-08-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2b20000e60, moduleTitle=Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6f2b20000e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594065, encodeId=d86c15940659e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, objectType=article, longId=199142, objectId=daaa19914221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daaa19914221, replyNumber=0, likeNumber=50, createdTime=2020-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daaa19914221, moduleTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=daaa19914221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594064, encodeId=e69215940643b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur J Cancer：HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物, objectType=article, longId=197255, objectId=bf6619e255f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf6619e255f5, replyNumber=0, likeNumber=48, createdTime=2020-07-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf6619e255f5, moduleTitle=Eur J Cancer：HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bf6619e255f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594063, encodeId=837515940638a, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur Urol：BRCA2基因组区域的前列腺癌风险评估 , objectType=article, longId=197246, objectId=6a7819e246ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7819e246ad, replyNumber=0, likeNumber=62, createdTime=2020-07-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7819e246ad, moduleTitle=Eur Urol：BRCA2基因组区域的前列腺癌风险评估 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6a7819e246ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594062, encodeId=58fd1594062aa, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, objectType=article, longId=196133, objectId=03921961335e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03921961335e, replyNumber=0, likeNumber=61, createdTime=2020-06-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03921961335e, moduleTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=03921961335e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594061, encodeId=3890159406171, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, objectType=article, longId=195327, objectId=2cf719532e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cf719532e2a, replyNumber=0, likeNumber=0, createdTime=2020-06-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cf719532e2a, moduleTitle=欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2cf719532e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

BRCA

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌

2021-05-14

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

J Clin Oncol：注意！携带BRCA1致病性突变的女性或卵巢储备功能下降！

2021-04-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Cancer：BRCA1/2-、CDK12-和ATM-突变的转移去势抵抗性前列腺癌的差异化治疗结果

2021-03-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur J Cancer：激素替代治疗使45岁以上BRCA突变携带者乳腺癌风险增加3倍！

2021-03-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制

2021-03-01

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究

2021-02-24

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Br J Cancer：携带BRCA2突变的乳腺癌患者的生存率分析

2021-02-21

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS

2021-01-24

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM双重磅：不仅是BRCA，乳腺癌风险与这些基因也密切相关！

2021-01-23

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

2021-01-14

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率

2021-01-10

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！

2020-12-15

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Clin Cancer Res：早期激素受体阳性乳腺癌患者的BRCAness和肿瘤炎症基因表达特征

2020-10-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Br J Cancer：ER表达状态对BRCA2突变型乳腺癌预后的影响

2020-09-23

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet oncol：PARP抑制剂veliparib联合卡铂-紫杉醇治疗BRCA突变的晚期乳腺癌的疗效

2020-08-30

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌

2020-08-12

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur J Cancer：HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物

2020-07-10

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur Urol：BRCA2基因组区域的前列腺癌风险评估

2020-07-10

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查

2020-06-21

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

欧洲药品管理局CHMP支持PARP抑制剂Lynparza，用于BRCA突变的胰腺癌维持治疗

2020-06-06

科室
- - 订阅+
  - 更多科室
工具
服务